Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis

PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings

OBJECTIVE. The objective of our study was to investigate whether phosphatase and tensin homolog (PTEN) expression is associated with clinicopathologic features and multiparametric MRI findings in prostate cancer. MATERIALS AND METHODS. Forty-three patients with prostate cancer who underwent radical prostatectomy were included. Index tumor was identified on pretreatment MRI and delineated in the area that correlated best with histopathology results. The apparent diffusion coefficient (ADC) from DWI and pharmacokinetic parameters derived from dynamic contrast-enhanced MRI (DCE-MRI) using the extended Tofts model (K^trans, k_ep, v_e, and v_p) within the tumor were estimated. The following clinicopathologic parameters were assessed: pretreatment serum levels of prostate-specific antigen, disseminated tumor cell status, age, Gleason score, tumor size, extraprostatic extension (EPE), tumor location, and lymph node metastases. Gene expression profiles were acquired in biopsies from the tumor using bead arrays, and validated using reverse transcription quantitative polymerase chain reaction (RT-qPCR) on a different part of the biopsy. RESULTS. Based on bead arrays (p = 0.006) and RT-qPCR (p = 0.03) data, a significantly lower ADC was found in tumors with low PTEN expression. Moreover, PTEN expression was negatively associated with lymph node metastases (bead arrays, p = 0.008; RT-qPCR, p < 0.001). A weak but significant association between PTEN expression, EPE (p = 0.048), and Gleason score (p = 0.028) was revealed on bead arrays. ADC was negatively correlated with Gleason score (p = 0.001) and tumor size (p = 0.023). No association among DCE parameters, PTEN expression, and clinicopathologic features was found. CONCLUSION. ADC derived from DWI may be useful in selecting patients with potentially aggressive tumor caused by PTEN deficiency.

Functional and Hybrid Imaging of Bone Metastases

Bone metastases are common, cause significant morbidity, and impact on healthcare resources. Although radiography, computed tomography (CT), magnetic resonance imaging (MRI), and bone scintigraphy have frequently been used for staging the skeleton, these methods are insensitive and nonspecific for monitoring treatment response in a clinically relevant time frame. We summarize several recent reports on new functional and hybrid imaging methods including single photon emission CT/CT, positron emission tomography/CT, and whole-body MRI with diffusion-weighted imaging. These modalities generally show improvements in diagnostic accuracy for staging and response assessment over standard imaging methods, with the ability to quantify biological processes related to the bone microenvironment as well as tumor cells. As some of these methods are now being adopted into routine clinical practice and clinical trials, further evaluation with comparative studies is required to guide optimal and cost-effective clinical management of patients with skeletal metastases. © 2018 American Society for Bone and Mineral Research.

Spatiotemporal features of DCE-MRI for breast cancer diagnosis

BACKGROUND AND OBJECTIVE

Breast cancer is a major cause of mortality among women if not treated in early stages. Previous works developed non-invasive diagnosis methods using imaging data, focusing on specific sets of features that can be called spatial features or temporal features. However, limited set of features carry limited information, requiring complex classification methods to diagnose the disease. For non-invasive diagnosis, different imaging modalities can be used. DCE-MRI is one of the best imaging techniques that provides temporal information about the kinetics of the contrast agent in suspicious lesions along with acceptable spatial resolution.

METHODS

We have extracted and studied a comprehensive set of features from spatiotemporal space to obtain maximum available information from the DCE-MRI data. Then, we have applied a feature fusion technique to remove common information and extract a feature set with maximum information to be used by a simple classification method. We have also implemented conventional feature selection and classification methods and compared them with our proposed approach.

RESULTS

Experimental results obtained from DCE-MRI data of 26 biopsy or short-term follow-up proven patients illustrate that the proposed method outperforms alternative methods. The proposed method achieves a classification accuracy of 99% without missing any of the malignant cases.

CONCLUSIONS

The proposed method may help physicians determine the likelihood of malignancy in breast cancer using DCE-MRI without biopsy.

A clinical application of dynamic contrast-enhanced CT (DCE-CT) in patients with variously differentiated breast ductal carcinoma

PURPOSE

To explore the hemodynamic characteristics of variously differentiated breast ductal carcinoma (BDC) using the dynamic contrast-enhanced CT (DCE-CT) based CT perfusion imaging (CTPI), including the specific perfusion parameter values, and to identify potential clinical applications in the cell differentiation degree of BDC.

MATERIALS AND METHODS

Forty patients with breast ductal carcinoma confirmed by needle puncture biopsy were studied prospectively using CTPI on a 64-slice spiral CT scanner. The acquired volume data were used for calculations, mapping, and analysis by using a tumor perfusion protocol in the CT perfusion software package to measure 4 parameters namely, blood flow (BF), blood volume (BV), mean transit time (MTT), and the permeability surface (PS) area product. The different differentiated BDC with CT perfusion parameters were divided into 3 groups of high, moderate and poor differentiation. The comparison among these groups were then made using statistical data analysis software.

RESULTS

The patients were categorized into three groups of 12, 13, and 15 highly, moderately and poorly differentiated ductal carcinoma cases, respectively. Comparing the perfusion parameters values of the three groups, BF, BV, and PS values increased from highly to poorly differentiated BDC cases. Differences between the highly and moderately or poorly differentiated groups were all statistically significant for BF, BV, and PS values (p < 0.05), while MTT value showed no statistical difference among the three groups (p > 0.05).

CONCLUSION

CTPI is a functional imaging technology from the perspective of hemodynamics with potential clinical applications. Three parameters of BF, BV and PS values have potential to serve as indicators of the cell differentiation degree of the breast ductal carcinoma.

Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis

Purpose: Bevacizumab, an antibody against endothelial growth factor, is a key but controversial drug in the treatment of metastatic breast cancer. We, therefore, aimed to determine the intrinsic resistance to bevacizumab at the physiologic and molecular levels in advanced breast cancer using PET, dynamic contrast-enhanced MRI, diffuse optical spectroscopic imaging (DOSI), and multiplex cytokine assays.Experimental Design: In total, 28 patients diagnosed with advanced stage III/IV breast cancer receiving single-agent bevacizumab for 1 week followed by paclitaxel combined with bevacizumab underwent ¹⁸F-fluorodeoxyglucose (FDG)-PET, ¹⁸F-fluoromisonidazole (FMISO)-PET, and MRI at both baseline and two courses after treatment initiation. Hemodynamic measurement using DOSI and blood sample collection were performed at baseline and multiple times during the first week after the initiation of single-agent bevacizumab. We distinguished nonresponders from responders by serial FDG-PET based on their glycolytic changes to chemotherapy.Results: Nonresponders showed significantly higher hypoxic activity on FMISO-PET and less tumor shrinkage than responders. Hemodynamic parameters showed higher tumor blood volume and a remarkable decrease in the tissue oxygen level in nonresponders compared with responders after the infusion of single-agent bevacizumab. Multiplex cytokine assays revealed increased plasma levels of both proangiogenic and hypoxia-related inflammatory cytokines in nonresponders and decreased levels in responders.Conclusions: Nonresponders exhibited a higher degree of angiogenesis with more severe hypoxia than responders during bevacizumab treatment. These findings demonstrated that the addition of bevacizumab to paclitaxel treatment under hypoxic conditions could be ineffective and may result in acute hypoxia and increased cytokine secretion associated with cancer progression. Clin Cancer Res; 23(19); 5769-78. ©2017 AACR.

Dynamic contrast-enhanced MRI detects acute radiotherapy-induced alterations in mandibular microvasculature: prospective assessment of imaging biomarkers of normal tissue injury

Normal tissue toxicity is an important consideration in the continued development of more effective external beam radiotherapy (EBRT) regimens for head and neck tumors. The ability to detect EBRT-induced changes in mandibular bone vascularity represents a crucial step in decreasing potential toxicity. To date, no imaging modality has been shown to detect changes in bone vascularity in real time during treatment. Based on our institutional experience with multi-parametric MRI, we hypothesized that DCE-MRI can provide in-treatment information regarding EBRT-induced changes in mandibular vascularity. Thirty-two patients undergoing EBRT treatment for head and neck cancer were prospectively imaged prior to, mid-course, and following treatment. DCE-MRI scans were co-registered to dosimetric maps to correlate EBRT dose and change in mandibular bone vascularity as measured by K_trans and V_e. DCE-MRI was able to detect dose-dependent changes in both K_trans and V_e in a subset of patients. One patient who developed ORN during the study period demonstrated decreases in K_trans and V_e following treatment completion. We demonstrate, in a prospective imaging trial, that DCE-MRI can detect dose-dependent alterations in mandibular bone vascularity during chemoradiotherapy, providing biomarkers that are physiological correlates of acute of acute mandibular vascular injury and recovery temporal kinetics.

Quantitative analysis of 3-Tesla magnetic resonance imaging in the differential diagnosis of breast lesions

The aim of this study was to investigate the value of quantitative 3-Tesla (3T) magnetic resonance (MR) assessment in the diagnosis of breast lesions. A total of 44 patients with breast lesions were selected. All the patients underwent MR plain scanning and T1 dynamic contrast-enhanced imaging. The vascular function parameters of the lesions, namely volume transfer constant (Ktrans), rate constant (Kep), extravascular extracellular volume fraction (Ve) and integrated area under the curve (iAUC), were acquired. These parameters were compared between benign and malignant breast lesions, and also among differential grades of invasive ductal carcinoma. The values of Ktrans, Kep and iAUC were significantly different between the benign and malignant tumors; however, the values of Ve in the benign and malignant tumors were not significantly different. The values of Ktrans, Kep and iAUC in invasive ductal carcinoma were significantly different between grade I and grade II, and between grade I and grade III; however, there was no significant difference between grade II and grade III. The Ve values in invasive ductal carcinoma did not significantly differ among grades I, II and III. Among the vascular function parameters, Ktrans exhibited the highest sensitivity and specificity in the differentiation of benign and malignant lesions. Quantitative 3-T MR assessment is valuable in the diagnosis of benign and malignant breast lesions. It can also provide reference values for the differentiation of the histological grade of breast invasive ductal carcinoma.